The European Consensus Conference has assessed the risk for thrombotic complications for most women undergoing gynecologic surgery and found it to be moderate. Nonetheless, it is important to analyze a patient's individual risk before surgery so that appropriate thrombosis prophylaxis can be given if increased risk is determined. Malignancy accounts for most thrombotic complications among gynecologic patients. Patients with known malignancies should receive prophylaxis during surgery, and some patients with breast cancer should receive prophylaxis during chemotherapy. Heparin, and low-molecular-weight heparin in particular, may favorably influence the outcome of cancer in some patients and treatment with these agents is currently under investigation in a number of trials as a new approach to anticancer therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0889-8588(05)70176-3 | DOI Listing |
Sci Rep
January 2025
Guizhou University of Traditional Chinese Medicine, Guiyang, 550000, Guizhou, China.
This study investigates the role of flavonoid Icaritin (ICT) in estrogen-deficient ovariectomized (OVX) female mice by activating the Estrogen receptor (ER)/ Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (Akt) signaling pathway, potentially delaying Parkinson's disease (PD) progression post-castration. Seventy-five 8-week-old C57BL/6J female mice underwent ovariectomy, followed by MPTP (20 mg/kg) injection for 7 days. ICT (20 mg/kg) was administered for 14 days, and motor function was assessed using various behavioral tests.
View Article and Find Full Text PDFZhonghua Fu Chan Ke Za Zhi
January 2025
Gynecological Minimally Invasive Center, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100006, China.
To investigate the correlation between uterine volume and intrauterine adhesion (IUA). From June 2018 to November 2019, totally 7 007 patients who underwent hysteroscopy in outpatient operating rooms of Gynecological Minimally Invasive Center, Beijing Obstetrics and Gynecology Hospital were retrospectively analyzed Patients of reproductive age with IUA without uterine fibroids and adenomyosis were selected as IUA group, and patients of reproductive age without uterine fibroids and adenomyosis without IUA during the same period were selected as the control group. The propensity score matching (PSM) method was used to perform 1∶1 matching for the two groups of patients, matching variables included age, height, weight, body mass index (BMI), gravidity, parity, and number of abortion curettage.
View Article and Find Full Text PDFInt J Gynaecol Obstet
January 2025
Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Objective: The objective of this paper is to study the association between obesity and tumor recurrence in patients with vulvar cancer.
Methods: This is a retrospective study including vulvar cancer patients from 2003 to 2022. Our primary outcome was progression-free survival (PFS) stratified by status of obesity, defined as body mass index (BMI) >30.
J Clin Med
January 2025
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-204 Szczecin, Poland.
Endometrial cancer is becoming an even more significant health concern in Poland, with incidence and mortality rates rising each year. : This retrospective study analyzed 1532 patients surgically treated for endometrial cancer at a single center in Poland between 2002 and 2020, examining changes in clinical and histopathological characteristics and their impact on patient outcomes over three time periods: 2003-2008, 2009-2014, and 2015-2020. : The study revealed significant shifts in tumor characteristics over time.
View Article and Find Full Text PDFJ Clin Med
January 2025
Gynecologic Oncology Unit, La Paz University Hospital, Paseo Castellana 261, 28046 Madrid, Spain.
Ovarian cancer is the fifth most frequent tumor in women and the second most common gynecological cancer. Recurrence of ovarian cancer develops in up to 50-90% of patients within the first five years after diagnosis. Approximately 70% of patients with advanced disease will experience a relapse.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!